The European Medicines Agency emphasizes that the benefits of the jab in protecting against COVID-19 still far outweigh the risks.

One hundred years after its invention, BCG has stood the test of time as a vaccine against tuberculosis.

In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.

The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.

Identifying molecular targets for SARS-CoV-2 therapeutics.

Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

The P.1 variant, which has also been detected in five US states, could be responsible for cases of reinfection, according to a preprint.

Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.